Geovax Labs, Inc. (GOVX) Stock Price & Analysis
Geovax Labs, Inc. (GOVX) fell 4.48% to USD 1.28 as of June 10, 2026 at 02:39 UTC, according to Nexqual real-time market data.
GOVX last closed at USD 1.34; the session ranged USD 1.22–1.5 on volume of 544,588 shares. Market capitalization is $6.67M, with a 52-week range of USD 0.96–34.75 (NCM). Source: Nexqual, June 10, 2026 at 02:39 UTC.
Key Statistics (as of June 10, 2026 at 02:39 UTC)
| Price | USD 1.28 |
|---|---|
| Change | ▼ 4.48% (down) |
| Previous Close | USD 1.34 |
| Open | USD 1.32 |
| Day Range | USD 1.22 – 1.5 |
| 52-Week Range | USD 0.96 – 34.75 |
| Volume | 544,588 shares |
| Market Cap | $6.67M |
| Exchange | NCM |
Technical Analysis (GOVX)
Nexqual's technical model rates GOVX "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.77 (neutral) |
| vs SMA50 | Below (USD 1.59) |
| MACD | -0 (negative) |
Analyst Ratings (GOVX)
Wall Street analysts rate GOVX "Strong Buy" based on 2 analysts, with a mean price target of USD 10 (range USD 10–10), per Nexqual as of June 10, 2026 at 02:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 10 |
| High Target | USD 10 |
| Low Target | USD 10 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (GOVX)
| Next Earnings Date | 2026-03-23 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -2.62 vs est -0.85 ▼ miss |
| 2025-09-30 | USD -7.75 vs est -6.63 ▼ miss |
| 2025-06-30 | USD -8.75 vs est -9 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Financials & Fundamentals (GOVX)
| Total Revenue | $852,282 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -2523.43% |
| Profit Margin | +0.00% |
| ROE | -509.28% |
| Debt / Equity | 79.91 |
| Current Ratio | 1.06 |
| Total Cash | $1.27M |
| Total Debt | $394,571 |
| Free Cash Flow | $-11.10M |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Financial Health Score (GOVX)
Nexqual rates Geovax Labs, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:39 UTC.
| Growth | Critical — Revenue -37% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $1M cash, no debt |
| Cash Flow | Weak — FCF negative: -$11M, burning cash |
| Efficiency | Critical — ROE -509%, ROA -194.6% |
Ownership (GOVX)
| Insider Ownership | +6.82% |
|---|---|
| Institutional Ownership | +9.85% |
| Shares Outstanding | 5.21M |
| Float | 3.47M |
| Short % of Float | +11.22% |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
Leadership (GOVX)
Geovax Labs, Inc. is led by David Alan Dodd (age 75), Chairman, President & CEO, per Nexqual as of June 10, 2026 at 02:39 UTC.
| Chairman, President & CEO | David Alan Dodd (age 75) |
|---|---|
| Chief Scientific Officer | Mark J. Newman (age 70) |
| Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board | Harriet Latham Robinson (age 87) |
| CFO & Corporate Secretary | Mark W. Reynolds (age 63) |
| Vice President of Quality Systems & Compliance | Thomas O'Brien |
Major Backers & Investors (GOVX)
Notable institutional backers of Geovax Labs, Inc. include Armistice Capital, LLC, Fidelity, Virtu Financial LLC, according to Nexqual as of June 10, 2026 at 02:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 5.17% |
| Fidelity | 0.67% |
| Virtu Financial LLC | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 0.69% |
| Vanguard Group | 0.22% |
Source: Nexqual, June 10, 2026 at 02:39 UTC.
From Geovax Labs, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States.
- It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine.
- In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox.
Partnerships
- It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BNBX | BNB Plus Corp. | USD 0.53 | ▼ 2.78% |
| VRAX | Virax Biolabs Group Limited | USD 0.19 | ▼ 11.64% |
| ADTX | Aditxt, Inc. | USD 0.03 | ▼ 53.39% |
| AEMD | Aethlon Medical, Inc. | USD 1.94 | ▲ 1.57% |
| LGVN | Longeveron Inc. | USD 0.77 | ▲ 5.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:39 UTC. This page is informational and not investment advice.